323: Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates

Jared Holz, a biotech stock and startup analyst, dives into the implications of the Federal Reserve's interest rate cuts on the biotech industry. He discusses the innovative use of cannabinoids in obesity treatments and the caution required in drug development. The conversation also highlights the prestigious Lasker Awards for significant contributions to GLP-1 hormone research. Additionally, Holz examines the challenges within the biotech market, including investor sentiment and competition in the obesity sector.